The table below shows Acrivon Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Operating cash flow
-$20.54M
-$19.54M
-$17.08M
-$11.36M
-$8.42M
Capital expenditure
$14.00K
$58.00K
$815.00K
$25.00K
$415.00K
Investing cash flow
$13.13M
$19.21M
$5.85M
$9.33M
-$415.00K
Dividends paid
-
-
-
-
-
Stock buybacks
-
-
ACRV operating cash flow (10-K history)
Acrivon Therapeutics, Inc. reported operating cash flow of -$63.66M for fiscal year 2025. That is up 3.1% from -$65.67M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$13.98M (FY 2021) to -$63.66M. Figures come from the company's audited annual reports as filed with the SEC.